MILabs’ preclinical imaging annual sales grows again by nearly 50%

//MILabs’ preclinical imaging annual sales grows again by nearly 50%

MILabs’ preclinical imaging annual sales grows again by nearly 50%


MILabs B.V. reported that for the third year in a row, the rapidly-innovating molecular imaging company has continued on its trajectory of strong preclinical imaging systems sales with another year-to-year rise close to 50%. 

“The dramatic increase in sales validates the design and functionality of our multimodal imaging platform and confirms that it enables new preclinical research applications, beyond the capabilities of any other system” stated Prof. Frederik Beekman, CEO of MILabs. “For instance, applications that were previously out-of-reach for preclinical researchers are now enabled by our high-performance PET-SPECT-CT-Optical imaging platform. These include advanced (3D) optical imaging, simultaneous PET/SPECT and multi-isotope PET translational research, multimodal nanomedicine, alpha- & beta radio-nuclide therapy monitoring and optical tomography. Through its unique design, our platform enhances the outstanding performance from each individual imaging modality with the synergetic capabilities offered by an integrated multimodal approach.”

Commitment to customers is another reason for the strong growth in sales. “Our products are user-friendly, and we offer excellent customer service and high reliability. We say what we deliver and we do it,” says Dr. Beekman.

Most importantly, MILabs will continue to invest significantly in imaging research. Dr. Beekman explains, “We have an established suite of imaging products, but what sets us apart is our investment in R&D. We bring our innovation results directly to our customers so that every imaging scientist can see more, learn more, and discover more”.

About MILabs

MILabs B.V. (Utrecht, the Netherlands) provides high-end molecular imaging solutions for biomedical and pharmaceutical research. With over 100 installations worldwide, these systems contribute significantly to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. For more information, visit or contact us at

2018-09-04T16:08:31+00:00April 9th, 2018|News|0 Comments